Close Menu

GenomeWebinars

Mon
Aug
24
1:00 pm2020
Sponsored by
Genecentric

Utility of Novel RNA-Based Tools in Oncology Drug Development

Genome Webinar

Director of the Lineberger Bioinformatics Core and Research Associate Professor of Genetics, University of North Carolina at Chapel Hill

Vice President of Discovery and Translational Science, GeneCentric Therapeutics

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Speakers will detail a range of topics, including how expression-based subtyping can eclipse DNA targeted panel technologies in determining patient’s likely response to treatment; the use of clinical subtypes and custom response signatures to select the right therapy for the right patient to improve treatment responses; and the identification of new tumor types for therapies.

Joel Parker of the University of North Carolina at Chapel Hill will discuss the identification of diverse molecular phenotypes with RNA-seq, focusing on expressed mutations, immune phenotypes, and viral detection and quantification.

Kirk Beebe of GeneCentric Therapeutics will follow with a presentation outlining the use of RNA-seq for bolstering drug development programs by circumventing mutational status and deciphering the functional expression of tumors. In particular, he will discuss how bulk tumor sequencing offers the ability to simultaneously assess diverse members of the tumor microenvironment such as cancer and immune cells and will share details of how this approach has been applied in both targeted and immunotherapies.

Sponsored by

Division of Cancer Genome Research,
German Cancer Consortium and German Cancer Research Center

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

The presentation will discuss a recent study addressing the longitudinal genotyping of circulating cell-free DNA (cfDNA) from patients with ALK rearrangements by combining panel-based deep sequencing with shallow whole-genome sequencing.

The results suggest that this liquid biopsy approach might be able to improve the care of ALK-mutated NSCLC patients through early detection of resistance mutations and indications of disease progression.

Thu
Sep
10
1:00 pm2020
Sponsored by
Genecentric

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Genome Webinar

Founder and Executive Partner, Opus Three

Senior Vice President, Clinical & Corporate Development, GeneCentric Therapeutics

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

The path to developing a companion diagnostic (CDx) is becoming increasingly complex as available technologies and therapeutic advancements outpace regulatory standards and procedures. RNA-based approaches require heightened awareness and vigilance in combination with a well-defined and robust bioinformatics process. This webinar will cover the processof developing RNA-based predictive response signatures for cancer therapeutics; clinical and therapeutic implications for this approach; and the regulatory requirements, tools, and milestones necessary for successful advancement of an RNA-based CDx.

Felix Frueh, founder of regulatory consultancy Opus Three, will provide a deep dive into the regulatory considerations of developing RNA-based companion diagnostics. He will contrast the development of companion diagnostics with non-companion diagnostics and will illustrate key differences using a series of examples. Particular emphasis will be paid to potential future RNA-based companion diagnostics and currently marketed RNA-based diagnostics.

Joel Eisner of GeneCentric Therapeutics will follow with a clinical and bioinformatics perspective on the development of RNA-based predictive response signatures as companion diagnostics. His presentation will touch on the development of prototype response signatures using in silico analysis of public datasets, the curation of retrospective clinical data to further develop prototype predictive response signatures, and other points.

Sponsored by

Chief Medical Officer, Basilea Pharmaceutica International

President and CEO, GeneCentric Therapeutics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Marc Engelhardt of Basilea Pharmaceutica International will discuss work showing that differential induction of gene expression may explain differences in reported adverse event profiles of targeted anticancer agents. His talk will detail the analysis of gene expression induction in safety relevant normal tissues from patient-derived xenograft models as an approach to rationalize and identify the molecular basis of adverse event profiles of targeted anticancer agents.

Michael Milburn, President and CEO of GeneCentric, will follow with a discussion of the utility of bulk tumor RNA-seq analysis in drug development. In particular, he will cover aspects of specimen and study design for bulk tumor genomics, as well as advantages and challenges of RNA-based diagnostics over DNA variations.  Development of immunogenomic analyses and GeneCentric’s overall technology approach will be highlighted.  This includes looking beyond RNA transcriptomics and utilizing RNA sequence data in drug development.

Sponsored by